All Programs

Use the tool below to view all available Series

Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
CME/CE
Navigating Treatment Sequencing After Frontline Treatment Failure in CLL
0.25 credits
- Jennifer R. Brown, MD, PhD
0.25 credits
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
CME/CE In-Person Event
Moving Beyond Sleep: The Broader Connection Between the Orexin System and Psychiatric Disorders
May 27, 2026
Miami Beach, Florida
1.00 credit Learn more
Tailoring Treatment: Can You Select the Best Therapy? 
Tailoring Treatment: Can You Select the Best Therapy? 
MinuteCE®
Tailoring Treatment: Can You Select the Best Therapy? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Switching Strategies: Switch or Stay—What’s Your Call? 
Switching Strategies: Switch or Stay—What’s Your Call? 
MinuteCE®
Switching Strategies: Switch or Stay—What’s Your Call? 
1.00 program credit
- David Rubin, MD
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
IBD Immunopathogenesis: Do You Know What You're Blocking?
IBD Immunopathogenesis: Do You Know What You're Blocking?
MinuteCE®
IBD Immunopathogenesis: Do You Know What You're Blocking?
1.00 program credit
- Kimberly D. Orleck, PA-C
- Brooke Hodnick, PA-C, MPAS
1.00 program credit
Remission: Can You Prove It? 
Remission: Can You Prove It? 
MinuteCE®
Remission: Can You Prove It? 
1.00 program credit
- David Rubin, MD
- Kimberly D. Orleck, PA-C
1.00 program credit
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
MinuteCE®
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?  
1.00 program credit
- Kimberly D. Orleck, PA-C
- Jennifer Geremia, PA-C
1.00 program credit
Minimal Hepatic Encephalopathy: A Covert Operation?
Minimal Hepatic Encephalopathy: A Covert Operation?
MinuteCE®
Minimal Hepatic Encephalopathy: A Covert Operation?
1.00 program credit
- Nancy S. Reau, MD
1.00 program credit
Hepatic Encephalopathy: More Common Than You Think
Hepatic Encephalopathy: More Common Than You Think
MinuteCE®
Hepatic Encephalopathy: More Common Than You Think
1.00 program credit
- Arun B. Jesudian, MD
1.00 program credit
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
MinuteCE®
Treatment of Hepatic Encephalopathy: When, What, How, and Why?
1.00 program credit
- Arun B. Jesudian, MD
1.00 program credit
MinuteCE®
Clearing the Brain Fog: Innovations in the Treatment and Management of Hepatic Encephalopathy
1.00 credit 9 episodes
- Arun B. Jesudian, MD
- Nancy S. Reau, MD
1.00 credit 9 episodes
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
CME/CE
Muscarinic Therapies as a Catalyst for Change: Addressing Clinical Inertia in Schizophrenia Care
0.25 credits
- Jose Rubio, MD
0.25 credits
Precision Treatment Pathways for MDD and Comorbid Insomnia
Precision Treatment Pathways for MDD and Comorbid Insomnia
CME/CE
Precision Treatment Pathways for MDD and Comorbid Insomnia
0.25 credits
- Michael E. Thase, MD
0.25 credits
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
CME/CE
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
0.25 credits
- Christoph U. Correll, MD
- Jonathan M. Meyer
0.25 credits
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
MinuteCE®
Distinguishing First-Line Treatment Adverse Event Profiles in HER2-Negative Upper GI Cancers
0.50 program credits
- James M. Cleary, MD, PhD
0.50 program credits

All Programs

Popular

Title

Share on ReachMD